Company intelligence / Profile preview

Mylan

Morgantown, West Virginia, United States

Ownership: Public · VTRS
Employees: ~35000
Development stage: Other

Overview

Mylan was one of the world’s largest generic and specialty pharmaceutical companies, with a broad portfolio of more than 7,500 marketed products and operations in over 165 countries; clinical programs ranged from generic launches to proprietary drugs such as "Maxzide" (antihypertensive) and "Eldepryl" (selegiline for Parkinson’s)

Therapeutic areas: ImmunologyEndocrinologyInfectious DiseasesGastroenterologyPulmonologyDermatologyCardiovascularOncologyNeurologyWomen's Health
Modalities: Small moleculeTransdermal patchBiologicAntiretrovirals
Industry: Pharma

Drug pipeline

1 asset

oestradiol

Approved

Partnerships

Watson Pharmaceuticals (Somerset joint venture)Lederle Laboratories (Maxzide distribution)Matrix Laboratories acquisitionMerck KGaA’s generics unit

Beyond the preview

Go deeper on Mylan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mylan.

Explore the full profile